CD276 and triple-negative breast carcinoma: Based on these principles, two preclinical studies were recently described with 212Pb-225.28 for the targeting of chondroitin sulfate proteoglycan 4 (CSPG4) overexpressed in triple-negative breast cancer and 212Pb-376.96 to the protein B7-H3 (CD276) in human pancreatic ductal adenocarcinoma (PDAC).